Zofran

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. .
[PubChem].

Medicinal name:
  • Ondansetron 4 MG Oral Tablet [Zofran]
  • Ondansetron 8 MG Disintegrating Oral Tablet [Zofran]
  • Ondansetron 4 MG Disintegrating Oral Tablet [Zofran]
  • Ondansetron 8 MG Oral Tablet [Zofran]

Zofran - Pharmacology:

Zofran is a selective serotonin 5-HT3 receptor antagonist. The serotonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine, and that the released serotonin then activates 5-HT3 receptors located on vagal efferents to initiate the vomiting reflex. Therefore Zofran works by blocking the reception of serotonin at these 5-HT3 receptors.

Zofran mini report

Zofran NDA
NDA - A product marketed under an approved New Drug Application
Zofran INTRAMUSCULAR; INTRAVENOUS
INTRAMUSCULAR; INTRAVENOUS
Zofran ORAL
ORAL
Zofran INJECTION
INJECTION
Zofran SOLUTION
SOLUTION
Zofran TABLET, FILM COATED
TABLET, FILM COATED
Zofran TABLET, ORALLY DISINTEGRATING
TABLET, ORALLY DISINTEGRATING
Zofran HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Zofran global name
ondansetron hydrochloride
Zofran global name
Ondansetron Hydrochloride
Start - Stop data
START DATA:
1991-Feb-04
Start - Stop data
STOP DATA
not occurred

Zofran Interactions

Zofran does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron. On the basis of limited available data, no dosage adjustment is recommended for patients on these drugs.

Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3

Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5

Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.

In a crossover study in 76 pediatric patients, I.V. ondansetron did not increase blood levels of high-dose methotrexate.

Zofran Contraindications

Zofran injection and Zofran injection premixed are contraindicated for patients known to have hypersensitivity to the drug.

Manufacturers name:

  • Cardinal Health
  • REMEDYREPACK INC
  • GlaxoSmithKline LLC

Generic name, Overdose, Half Life Zofran, Food Interactions, Chemical, etc..

Zofran see also FDA report

Brand Names containing Ondansetron
Cancer